Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180232 | 0.82 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4174473 | 0.80 | CHRM3 (0.49) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4182174 | 0.79 | CHRM3 (0.56) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4176964 | 0.76 | ALDH1A1 (0.51) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4172954 | 0.73 | CHRM3 (0.46) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4177298 | 0.73 | CHRM3 (0.56) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| Trifluoroacetic Acid SCHEMBL18422703 | 0.72 | PDK1 (0.41) | MAPTBRD4ROCK2ARHGDIAROCK1 | |
| Trifluoroacetic Acid SCHEMBL18422700 | 0.72 | PDK1 (0.41) | MAPTBRD4ROCK2ARHGDIAROCK1 | |
| SCHEMBL4174389 | 0.71 | CHRM3 (0.49) | CHRM3CHRM2CHRM1BRD4ROCK2 | |
| SCHEMBL4966861 | 0.70 | MAPT (0.50) | MAPTROCK2ARHGDIAROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | US | claimed |
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | US | disclosed |
| EP-1968980-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007110782-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM5 | CHRM3 5/4885CHRM2 1/4885CHRM4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.